What was the primary driver of the significant increase in net earnings for the quarter?

The primary driver of the significant increase in net earnings was a $622 million pre-tax gain recognized from the termination of the acquisition agreement with Guidant Corporation. This one-time event significantly boosted the company's 'Other Income' and contributed substantially to the net earnings growth.

How is the Pharmaceutical segment performing, given the challenges mentioned?

The Pharmaceutical segment saw a slight sales decrease of 2.2%. While facing generic competition for some products like DURAGESIC(R) and hormonal contraceptives, key products such as RISPERDAL(R)/RISPERDAL(R) CONSTA(R), REMICADE(R), and TOPAMAX(R) demonstrated strong operational growth. The company is actively managing patent challenges and generic threats.

What is the outlook for the Medical Devices and Diagnostics segment?

The Medical Devices and Diagnostics segment showed robust performance with a 4.5% sales increase. The Cordis franchise, particularly with its CYPHER(R) stent, was a significant contributor. The segment also benefited from strong performance in DePuy's orthopaedic products and Ethicon Endo-Surgery's offerings. The company is addressing FDA-related quality system matters for Cordis.

What is the company's strategy regarding shareholder returns and capital allocation?

Johnson & Johnson continues to prioritize shareholder returns. The company announced an increased quarterly cash dividend, marking its 44th consecutive year of dividend increases, and approved a new $5 billion stock repurchase program. This reflects confidence in its financial position and commitment to returning value to shareholders.

JNJ 10-Q Quarterly Report Q2 FY2006 — Revenue, Net Income, EPS

Summary

Johnson & Johnson (JNJ) reported first quarter 2006 results showing modest worldwide sales growth of 1.2% to $13.0 billion, driven by operational increases of 3.5% offset by a negative currency impact of 2.3%. The company's diverse segments demonstrated varied performance: Consumer sales grew 3.3%, Pharmaceuticals saw a slight decline of 2.2% (with key products like RISPERDAL(R) and REMICADE(R) showing strength despite generic pressures), and Medical Devices & Diagnostics reported a solid 4.5% increase, boosted by the Cordis franchise. Net earnings increased significantly to $3.3 billion from $2.8 billion in the prior year's comparable quarter. This improvement was largely influenced by a $622 million pre-tax gain from the termination of the Guidant acquisition agreement, which significantly boosted 'Other Income' and the effective tax rate. Despite ongoing litigation and patent challenges, particularly in the pharmaceutical sector, JNJ's strong operational performance and strategic acquisitions underscore its resilience. The company also continued its commitment to shareholder returns, increasing its quarterly dividend and actively repurchasing shares.

Key Highlights

1Worldwide sales increased 1.2% to $13.0 billion, with operational growth of 3.5% partially offset by currency headwinds.
2Net earnings rose to $3.3 billion from $2.8 billion year-over-year, significantly boosted by a $622 million pre-tax gain from the termination of the Guidant acquisition.
3The Pharmaceutical segment experienced a 2.2% sales decline, impacted by generic competition, though key products like RISPERDAL(R) and REMICADE(R) showed strong growth.
4Medical Devices & Diagnostics segment sales grew 4.5%, led by the Cordis franchise's strong performance, particularly the CYPHER(R) stent.
5The company's effective tax rate increased to 28.4% from 27.7%, partly due to the Guidant termination fee being taxed at a higher rate.
6JNJ increased its quarterly cash dividend by 15.8% to $0.33 per share and authorized a new $5 billion stock repurchase program.
7Research and development expenses increased by 10.7% to $1.5 billion, reflecting increased investment in late-stage pharmaceutical projects and other segments.

JOHNSON & JOHNSON Quarterly Report for Q2 Ended Apr 2, 2006

Summary

Key Highlights

Frequently Asked Questions